Patients with unresectable stage III non-small cell lung cancer taking durvalumab had significantly better overall survival than those on placebo after standard chemotherapy and radiation, according to the… read more.
The ALK- and ROS1-inhibitor brigatinib showed a better progression-free survival (PFS) compared to the ALK-inhibitor crizotinib in the first interim analysis of a head-to-head trial in patients with… read more.
Professor Gail Darling (WCLC co-President, Toronto, Canada) discusses the success of combined screening and smoking cessation pilot in Ontario.
Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) and Professor David Baldwin (Nottingham, UK) detail current UK pilots and a screening protocol that is currently going through the NHS England… read more.
A randomised, controlled screening trial for lung cancer involving almost 16,000 people in the Netherlands and Belgium found that CT screening produced a 26% reduction in lung cancer… read more.
The IASLC 19th World Conference on Lung Cancer (WCLC) was full of highlights, including 3 plenary abstracts being presented in the New England Journal of Medicine and involvement from… read more.
Inflammatory bowel disease can have a detrimental impact of health-related quality of life, and reducing the physical and psychological disease burden is an important therapeutic target. Patient-reported outcomes… read more.
To have a chance of preventing IBD clinicians need to be able to predict who is at risk, based on sensitive and selective risk factors. In a translational… read more.
IBD specialists have more treatment options than ever before; yet the optimal use of many agents, old as well as new, remains to be defined. A plenary session… read more.
Perianal fistulas remain a debilitating complication for CD patients, with high levels of morbidity and impact on quality of life. Several abstracts and posters at DDW 2018 addressed… read more.
This article summarises some of the key study updates presented at DDW 2018.
Professor John Lafrate (Harvard Medical School, Boston) and Professor Frank Detterbeck (Yale School of Medicine, New Haven) spoke in a session looking at some of the difficulties with diagnosis and… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
